Biostime taps dollar bond to fund CB tender

Chinese infant formula manufacturer is looking to make its debut international bond offering to partially finance the repurchase of its outstanding convertible debt.

Chinese baby formula manufacturer Biostime International plans to restructure its balance sheet through a tender offer of its outstanding HK$3.1 billion $400 million convertible debt and a new Reg S144A senior bond issue, the company said on Monday.

The move is taking place after the company spent A$1.4 billion $992 million last year acquiring a controlling 83% stake in Swisse Wellness, the Australian health supplements and vitamins company. Biostime’s cash and cash equivalents was down 64% year-on-year to Rmb1.2 billion $183 million as of the end of 2015.

The company aims to take advantage of the relatively low interest rate...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222